Clinical

Krystyn Van Vliet, PhD, vice president for research and innovation at Cornell University, discusses MS drug discovery barriers and overcoming them using 3D platforms.

Two existing, well-validated patient-reported outcome (PRO) measures may be useful as a prognostic marker for mortality and assist with treatment selection for patients with cutaneous chronic graft-vs-host disease (GVHD).

Marisa McGinley, DO, explains how technology can help improve access to multiple sclerosis (MS) care.

Experts discuss oral SERDs in the pipeline, clinical pathways for treatment of breast cancer, and strategies to help ensure patients have access to treatment. The participants also describe diverse agents in development, including their toxicity profiles.

Investigators were searching for answers to the question, “Does it matter if a vein- or artery-first approach is used when performing a robotic lobectomy for non-small cell lung cancer (NSCLC)?

With little data available on outcomes among patients who have B-cell lymphoma (BCL) and secondary central nervous system (CNS) involvement who were administered CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, these investigators enrolled 4 male patients in their study.

According to the authors, these improvements may be part of the reason why there was a lower rate of major adverse cardiovascular events in the REPRIEVE study.

The Mendelian randomization–based analysis, which examines how variation in genes have a causal effect of an exposure on certain outcomes, identified 12 gut microbiota associated with either an increased of or protective effect against MG.

The pump had varying success in reaching recommended glycemic targets among the study participants with type 1 diabetes (T1D).

In younger patients with chronic lymphocytic leukemia (CLL), treatment with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFRC) led to strong progression-free survival (PFS) and durable remission years after treatment.

The patient had both classical Hodgkin lymphoma and diffuse large B-cell lymphoma.

After being found effective over longer durations with smaller doses, this study found that nipocalimab infusions resulted in a tolerable safety profile and remained effective even in shorter treatment periods and with larger doses.

A rare mutation on the BCL6-corepressor gene correlated with worse overall survival in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, allogenic stem cell transplant improved survival in this population.

The analysis revealed that viral hepatocellular carcinoma (HCC) had a distinct microbial signature vs non-viral HCC, although only hepatitis B virus–related HCC showed a significantly diverse tumor microbiome.

Improvement across all asthma control parameters was achieved after 12 months of biologic treatment, according to one study.

Outside of a gait laboratory, this investigation compared gait pattern differences between children who have Duchenne muscular dystrophy (DMD) and their typically developing counterparts to gain more real-world data of DMD-associated gait characteristics.

Investigators say the findings could lead to new therapeutic targets.

Congress is unlikely to include many major health care priorities in the next government funding package; many adults continue to see racism as a problem across aspects of US society; the Endocrine Society will review its clinical guidelines for gender-affirming care.

Patients with colorectal cancer (CRC) who were also frail were found to have worse survival when compared with patients who weren’t frail.

Ronald D. Alvarez, MD, MBA, discusses challenges in implementing updated NCCN guidelines, such as coverage limitations imposed by payers.

The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.

Patients with cancer express shock and anxiety over the recent ruling by the Alabama Supreme Court regarding frozen embryos; doctors are beginning to charge fees for administrative tasks; some universities are implementing accelerated nursing programs to help with the shortage.

The systemic immune-inflammation index (SII) was found to be a potential predictor of the prognosis of patients with chronic obstructive pulmonary disease (COPD).

Patients with chronic lymphocytic leukemia (CLL) who discontinued ibrutinib had higher rates of adverse events compared with those who continued the therapy, the authors found.

Camilla Levister, MS, ANP-C, CDCES, a nurse practitioner at the Icahn School of Medicine at Mount Sinai Hospital in New York, gives insight into the nuances of testing closed-loop insulin delivery systems for pregnant women.